LucyRx Chief Commercial Officer, Susan Thomas, recently authored an article for Pharmaceutical Executive on how direct-to-consumer (DTC) prescription care is evolving into a more connected, clinically guided model.
In her article, Susan traces the DTC journey from its early days, when privacy-seeking patients discreetly received medications like Viagra, to the variety of pharmaceuticals available today for patients who find the direct channel convenient and cost-effective.
“When done right, DTC can be a powerful strategy for cost containment, member engagement, and even clinical improvement. Employers who pay attention to this trend, and partner with the right solutions, can reduce waste, expand access, and strengthen the value of their benefit offerings,” she wrote.
Susan also details the forces driving demand for increased DTC options, including high-deductible health plans and denials; rebate fatigue; and fragmented pharmacy access.
Importantly, she notes that patients who receive medication directly from the manufacturer should not feel isolated in their care journey. For example, many people taking GLP-1s for weight loss find greater success when the medication is paired with coaching and education.
Share